Polysaccharide from Anemarrhena asphodeloides treats diabetic rats / 中成药

ABSTRACT

AIM To explore the therapeutic effects of polysaccharide from Anemarrhena asphodeloides Bunge (PAA) on diabetic rats and potential mechanism of action.METHODS The rat model for diabetes was established by intraperitoneal injection of STZ (60 mg/kg),and sixty rats were assigned to control-,model-,glibenclamide-(25 mg/kg) groups and three groups of PAA-(50,100,200 mg/kg).Drugs were intragastrically administrated to rats once a day for 28 days.The rat body weight,glucose tolerance,fasting blood glucose (FBG),fasting insulin (FINS),IL-6,TNF-α,CAT,SOD,MDA,insulin receptor substrate (IRS1),Phospho-IRS1 and glucose transporter protein 4 (Glut4) were tested.RESULTS PAA could increase rat body weight and FINS level,reduce FBG level,and improve the glucose tolerance.The levels of IL-6 and TNF-α in serum,and MDA content in hepatic tissue were decreased,and the activities of CAT and SOD in hepatic tissue were increased.Meanwhile,PAA could also reduce the Phospho-IRS1 expression,and increase the Glut4 expression in hepatic tissue.CONCLUSION PAA has an anti-diabetic effect,whose mechanism is involved in anti-inflammatory,antioxidation,decreasing Phospho-IRS1 expression,and increasing Glut4 expression.